GLP-1s and Breast Cancer Risk: What New Research Shows
There's a headline making the rounds right now, and it deserves a careful read rather than a quick share.
What the study found
Researchers at the University of Pennsylvania reviewed health records from more than 111,000 women ages 45 to 80 who were overweight or obese. Women taking GLP-1 medications were roughly 30% less likely to be diagnosed with breast cancer than women who weren't.
The association held after accounting for age, race and ethnicity, BMI, breast density, and diabetes. The work was presented at the 2026 ASCO Annual Meeting and published in JCO Oncology Practice.
The caveat that matters
This was an observational study. It found a pattern, not a cause.
The researchers have said so directly, and the American College of Radiology is calling for a large prospective trial to determine whether these medications actually prevent breast cancer or whether something else about the women taking them explains the gap.
We're telling you this because you deserve the full picture. A GLP-1 is not a cancer prevention drug, and no one should start one for that reason.
Why metabolic health and cancer risk are connected
What this research reinforces is something we discuss with patients every week: your metabolism and your long-term disease risk are not separate conversations.
Body fat isn't inert tissue. It produces estrogen, and after menopause it becomes a woman's primary source of it. More fat tissue means more circulating estrogen, which is part of why obesity is an established risk factor for postmenopausal breast cancer. Layer on chronic inflammation and insulin resistance, and you have an internal environment working against you. WORTH NOTING....Endogenous estrogen from adipose tissue and prescribed menopausal estradiol are NOT the SAME exposure.
Here's the part worth sitting with: excess weight is one of the few breast cancer risk factors you can actually change. You can't change your age, your genetics, or your family history. You can change your metabolic health.
How we approach GLP-1 therapy at Next Phase of Health
We don't write a prescription and send you on your way. A GLP-1 is one tool inside a larger plan.
Real labs first. Metabolic markers and a full hormone panel, because weight and hormones are rarely separate problems, especially in perimenopause.
Muscle protection. Protein targets and strength training, because losing muscle alongside fat is the fastest way to undo your own progress.
Regular follow-up. We adjust as your body changes rather than leaving you on one dose indefinitely.
Screening stays on schedule. Mammograms still matter. Nothing in this research changes that.
Frequently asked questions
Do GLP-1 medications prevent breast cancer?
No. Current research shows an association between GLP-1 use and lower breast cancer incidence, but observational studies can't establish cause. GLP-1 medications are not approved for cancer prevention.
Does losing weight lower breast cancer risk?
Excess body weight is an established risk factor for postmenopausal breast cancer, largely because fat tissue produces estrogen after menopause. Improving metabolic health addresses one of the few modifiable risk factors available.
Is GLP-1 therapy covered by insurance?
Coverage varies widely by plan and diagnosis. Compunded GLP-1s are not covered by insurance.
Where can I get GLP-1 weight management near Glenview, IL?
Next Phase of Health provides medically supervised GLP-1 therapy, hormone optimization, and metabolic wellness care in Glenview, serving patients across Chicago's North Shore.
Let's talk
If you've been curious about GLP-1 therapy, or you're already on one and want a more thoughtful approach, we'd love to sit down with you.
We currently accept Blue Cross Blue Shield PPO, with Aetna, UnitedHealthcare, and Cigna coming soon.
Next Phase of Health
This article is educational and is not medical advice. GLP-1 medications are not FDA-approved for cancer prevention. Talk with your clinician about what's right for you.
Comments